zepbound novo nordisk

Lilly, Zepbound

Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company's lead in the fast-growing market.

· 12d · on MSN

Eli Lilly slashes Zepbound prices: Check out the updated costs and where to buy the weight-loss drug

· 13d · on MSN

Eli Lilly cuts Zepbound prices in competitive weight loss drug market battle

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

13don MSN

Lilly Cuts Low-Dose Zepbound Price for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

NBC 6 South Florida

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in ...

BioSpace

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...

ABC Columbia

Eli Lily cuts price for Zepbound

Monday, Dec. 1, Eli Lilly announced Zepbound will cost less for those who buy the medication straight from the drugmaker.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results